CGBIO announced on the 17th that its PDRN (polydeoxyribonucleotide)-based skin booster “DeCLARÉ PDRN” has received approval for an Investigational Device Exemption (IDE) for a clinical trial from the Ministry of Food and Drug Safety and will begin full-scale clinical testing.

The clinical trial will enroll 366 male and female adults aged between 19 and 65, with the aim of securing an indication for improvement of periorbital wrinkles. The study, scheduled to begin at the end of May, will involve administering the product to wrinkles around both eyes and then evaluating its safety and efficacy.

DeCLARÉ PDRN is designed to reduce pain during injection and concerns over immediate post-procedure embossing and nodules, issues that have been raised with existing PDRN product lines. Developed on a high-purity, low-viscosity basis, it is characterized by a relatively smooth injection feel and even distribution within the skin.

Accordingly, the company explained that its potential use has been expanded not only for thin and sensitive areas such as around the eyes, but also in cases requiring repeated procedures.

Following the launch last year of “DeCLARÉ CaHA,” a CaHA-based collagen booster, CGBIO is expanding its skin booster lineup with this new PDRN product. By building a product portfolio that can be selected according to skin condition and treatment purpose, the company plans to strengthen its responsiveness in the aesthetic market.

Yoo Hyun-seung, CEO of CGBIO, stated, “Through this clinical trial, we plan to verify the product’s safety and efficacy and continue development with the goal of launching in 2027,” adding, “We are also considering entry into global markets in the future.”

Popular News